NDA for icotrokinra for the treatment of adults and adolescents 12 years of age and older with moderate to severe plaque ...

Key Points GAAP loss per share of $0.55 in Q2 2025 beat analyst estimates by $1.13. GAAP revenue of $5.5 million in Q2 2025 missed expectations by 26%. Advanced key clinical programs, with first U.S.

Johnson & Johnson (NYSE:JNJ) is one of the best trade‑war resistant stocks to buy now. On July 21, 2025, J&J submitted a New Drug Application to the U.S. FDA for icotrokinra, an oral peptide therapy ...

Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor Filing based on unprecedented data package that met all primary endpoints across ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

Johnson & Johnson JNJ delivered strong second-quarter 2025 results, with both the top and bottom lines exceeding expectations ...

HIGHLIGHTS March 2025 Tolmer discovery hole ranked 5th highest-grade silver intersection reported globally during H1 2025, with an interval of 6m @ 4,747 g/t Ag from only 46m depth1 New assays have ...

Gryphon Stockholder Voting Has Commenced for Special Meeting to Be Held on August 27, 2025 Gryphon’s Board of Directors ...

LAFAYETTE, LA / ACCESS Newswire / August 6, 2025 / Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), an ...

Oekoboiler Swiss AG, known for leading in Switzerland’s manufacturing sector, has announced its new way of offering ...

WHITBY, ON / ACCESS Newswire / August 6, 2025 / Consumer Choice Award is pleased to announce the 2025 award recipients in the ...